One question of particular importance in phase III HIV vaccine trials is the choice of efficacy measure (EM) to validly and precisely estimate the true vaccinal efficacy. Traditional EMs, based on hazard rate ratio (HRR) or cumulative incidence ratio (CIR) are time-sensitive to mode of vaccine action and population heterogeneities. Through Monte-Carlo simulation, the performance of HRR and CIR based EMs are examined across different trial designs and vaccine and population characteristics. A new EM based on log-spline hazard regression (HARE) is proposed. Given that vaccinal properties (mode of action, time-lag, waning) are unknown a priori, appropriate selection of EM is problematic, and HRR and CIR can be unreliable to estimate the true maximum efficacy of candidate products. Non-random sexual mixing can exacerbate biases in HRR and CIR. HARE can offer valid estimation across different modes of vaccine action and in presence of frailty effects, contrary to its traditional counterparts. Our simulation studies highlight the weaknesses of widely used EMs while offering guidelines for trial design and suggesting new avenues for statistical analysis.
INTRODUCTION
The planning of clinical trials of candidate HIV-1 vaccines presents many methodological, ethical and financial problems. Because of the need for vaccines to slow the spread of HIV-1 in most countries of the world, governmental and international agencies have been preparing for phase III trials for candidate products that are in the phase I (safety) or phase II (immunogenicity) stages of evaluation [1] . The purpose of a phase III trial is to test the efficacy of the product under natural conditions of exposure to infection. In the design of such trials, two key issues are the choice of a statistical measure of efficacy (EM) that will estimate in an unbiased manner the true * Author for correspondence. efficacy of the vaccine (VE), and the appropriate sample size to achieve a desired degree of precision in this measurement. The question of sample size can only be addressed after making a decision on the precise form of the EM.
Unfortunately, the method widely used in studies of vaccine efficacy, namely, the randomized double-blind treatment and placebo clinical trial, does not guarantee validity and precision in efficacy measurement because of many heterogeneities that may influence exposure and infection in a differential manner in the treated and untreated arms during the course of the trial. For HIV-1, these include variability in the degree and duration of immunity post vaccination (due to genetic heterogeneity in both host and virus populations), heterogeneity in exposure to infection both over time (the stage of the epidemic) and between patients (e.g. due to different sexual behaviours), and viral evolution during the conduct of the trial in the study population.
The validity of traditional EMs, based on hazard rate ratios (HRR) or cumulative incidence ratios (CIR), depends whether key assumptions on which these statistics are based are indeed satisfied in any given trial. These are independence of infection events, proportionality of risks and equality in exposure within the control and treated groups. Studies have suggested that such key assumptions may present difficulties in HIV-1 vaccine trials due to a lack of independence in events [2] [3] [4] , biases within the study population arising from heterogeneity in sexual behaviour [5] and the mode of action of candidate vaccines [6] [7] [8] . These issues are considered in more detail in the context of HIV-1 in the following section before examining their effect on reliability of the traditional EMs in double-blind randomized controlled trial designs.
The measurement of efficacy
A key problem in the measurement of efficacy is that of dependency between exposure and infection events within the study population. In populations in which HIV-1 is transmitting between infected and susceptible individuals, the rate at which new infections arise is dependent on the numbers of infected and susceptible people in previous time intervals. As such, observations on the rate of infection (number of new infections in a given time interval) of different members of the study population will be interdependent. This process often produces a pattern of spread where the incidence rises rapidly, reaches a peak and then falls to a stable level if the infection becomes endemic [9] .
Heterogeneity in sexual behaviour is a further complication [10, 11] . How it acts on EMs in randomized trials is not immediately clear, but it will give rise to frailty selection which may undermine the benefit of the initial randomization. More precisely, individuals in high sexual activity classes will, on average, acquire infection earlier in the trial than individuals with low activity. Thus, as the trial progresses, the uninfected controls will tend to belong to the lower sexual activity classes, by comparison with the uninfected vaccinees (given that the vaccine provides some protection against infection), eventually inducing differential exposure between control and treated groups.
The properties of the vaccine will perhaps have the greatest effect on the choice of an EM. At one extreme, a vaccine may act to reduce the susceptibility of all vaccinees to infection upon exposure (of a defined type) with an infectious person by a constant fraction, δ. We refer to this mode of action as Model 1 (α l 1, 0 δ 1). At the other extreme the vaccine may confer complete protection to only a fixed proportion of the vaccinees, α. We refer to this case as Model 2 (0 α 1, δ l 1). Previous studies have suggested that the hazard based EMs (e.g. HRR) are more appropriate for Model 1 while proportion based measures (e.g. CIR) are better for Model 2 [6] . In practice, the properties of a vaccine may lie between these extremes and we refer to this situation as the Mixed Model (0 α 1, 0 δ 1). Alternatively, the reduction in susceptibility in those who respond to immunization (i.e. it provides some protection) may vary from one individual to another. We call this the Distributional Model (0 α 1, 0 δ i 1, for individual i). Further complications are introduced if the action of the vaccine alters over time due either to a waning in protection, or to a delay in the generation of a protective response post immunization (time-lag). In absence of prior knowledge on the HIV-1 vaccine and certain population characteristics, all these factors considered together highlight the need for a robust statistical EM that is reliable for a diverse array of circumstances.
Statistical and mathematical studies of vaccine efficacy
In an early study of vaccine efficacy measurement, Smith and colleagues [6] noted the time-dependency both of incidence based EMs under the assumption of Model 2, and simple proportions under the assumption of Model 1. This problem was also highlighted by Greenland and colleagues [7] who demonstrated timedependence in both measures under a Mixed Model. More recently, an increasing number of researchers have used mathematical models of infectious agent transmission to consider the adequacy of trial designs and EMs [2, 8, [12] [13] [14] [15] [16] [17] [18] [19] [20] [21] [22] [23] . For example, studies by Svenssen [17] demonstrated that in a stable closed population with heterogeneity in susceptibility to infection (either due to behaviour or genetic background) their Model 1 estimator (a logarithmic Simulation studies of HIV-1 vaccine transformation of CIR or attack rates) will be negatively biased. On the other hand, positive bias in the estimator may occur when the mode of vaccine action is heterogeneous within the trial population. Haber and colleagues [12] showed in the context of acute outbreaks in a closed homogeneous randomly mixing population that validity of vaccinal efficacy measurement using their Model 1 estimator depended on the fraction vaccinated even under a Model 1 mode of vaccine action. However, under a Model 2 vaccine an EM based on simple proportions of attack rates behaved adequately. They generalize the results to consider heterogeneity in transmission rates and demonstrate that the traditional EMs can have considerable bias [13] . Extending results to consider non-random mixing, analyses revealed further that the EMs that presuppose random mixing can be very biased [14] . On the basis of these results Haber and colleagues [14] proposed an EM that takes account of contact patterns between members of the population. Although bias improved, use of the proposed new estimator in HIV vaccine trials would depend on knowledge of sexual contact patterns between sexual activity classes which is rarely available in practice.
Halloran and colleagues [8] employed a stochastic simulation model to examine the effect of heterogeneity in vaccinal protection. They showed that their Model 1 and Model 2 estimators can provide confidence bounds for the mean vaccinal efficacy estimate. Halloran and colleagues [15] also examined the performance of EMs based on transmission probabilities, hazard ratios and attack rates under Models 1 and 2 with the assumption that vaccinees increase exposure by adopting high risk behaviours in the belief that they are fully protected against infection. They showed that EMs are very sensitive to the assumption of increased exposure and may even adopt negative values interpreted as an immunosuppressive effect of vaccination. To palliate for this difficulty, they proposed a measure based on transmission probabilities. Although less sensitive, this parameter is difficult to measure in practice. Halloran and colleagues [16] also use frailty mixing models to conclude that heterogeneities in susceptibility or exposure generally lead to underestimations in efficacy estimates.
Other studies reveal the sensitivity of vaccine efficacy measures to various forms of heterogeneity but in the majority of cases the model framework is not geared specifically for phase III trials for HIV candidate vaccines [18] [19] [20] . Some discuss trials designed to measure aspects of vaccination other than direct effects on vaccinees, such as measurement of reduction in infectiousness or population effectiveness [21, 22] . Others yet do not embark directly on the question of EMs, but on other questions in the context of HIV dynamics and control. These include deterministic studies of eradication criteria in defined populations [24] , the influence of the phase of the epidemic on biases in the recruitment of patients for trials [25] , the significance of time varying effects on estimation during the trial [23] , as well as others [26] [27] [28] .
These studies highlight many problematic sources of heterogeneity that can act within study populations exposed to HIV infection. To date most of the available results have been derived under several assumptions such as closed or small populations, observational studies, sexually homogeneous populations, random mixing, equal exposure to infection or constant baseline hazard or incidence. To our knowledge, few or no studies investigating EMs consider specifics such as sex, cohort type or staggered entry in a randomized double-blinded controlled vaccine trials embedded in a much larger population in which HIV is not at equilibrium. Few (or none) account for biological specifics of HIV such as transmission probabilities that vary within the three phases of HIV infectivity necessary to better represent HIV dynamics, incidence and prevalence. Furthermore, few (or none) investigate the importance of the Distributional Model, time-lag or waning properties of vaccination on EMs.
In an effort to assist in the planning of phase III trials and in the interpretation of trial results, we study how different sources of heterogeneity influence the traditional EMs based on hazard rates (HRR) on simple proportions (CIR) in large double-blind controlled trials. The aim is to find which measure has the greatest precision and the least bias, given the complex nonlinear dynamics of HIV transmission. While we may not be able to control for all the different influences, it will be important (for clinicians, public health specialists, etc.) to know their effects in order to interpret well the results and to know when to be confident or reserved with respect to conclusions. Lastly, in an endeavour to improve estimation, EMs based on hazard estimation (HARE) and hazard regression (HEFT) [29, 30] , an adaptive log-spline technique for estimation of conditional hazard functions apt to deal with time dependent data, is introduced. 
are HIV susceptibles respectively in the general population, controls, vaccinees with developed immunity, vaccinees with undeveloped immunity, and vaccinees who do not take (vaccine failures). Similarly X j Table 2 . Forces of infection λ(t) and λ*(t) are detailed in Appendix 1.
METHODS

The mathematical model
A compartmental stochastic model serves as the template to mirror different features of phase III trial design and HIV transmission. The model consists of five disease states (h l 1, …, 5) representing the different stages of progression from susceptibility, to infection, to AIDS (Fig. 1 a) . Susceptibles are labelled by the superscript h l 1, full blown AIDS patients by h l 5, and three stages of progression from HIV infection (with different degrees of infectiousness) as h l 2, 3 and 4. The sexually active population is stratified by sex (k l 1 for women, and k l 2 for men) and by sexual activity defined by the rate of sexual partner acquisition. Six activity classes are defined (i l 1, …, 6) where at one extreme are individuals of low sexual activity (i l 1, 2) and at the other are high activity individuals such as female commercial sex workers (CSW) and male clients of sexually transmitted disease clinics (MCSC) (i l 3, …, 6). The number of individuals in disease state h, activity class i and of sex k, is given by X h k,i (t). Transition between states occurs by infection, progression to disease, Simulation studies of HIV-1 vaccine 
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death or immigration into the population at rates where the time between events is assumed to be exponentially distributed. The rate at which any event occurs, R(t), in a population of size
where r counts the different events. Given a stratification of two sexes and six sexual activity classes, 120 mutually exclusive events can occur (2 sexesi6 classesi10 possible events) in the absence of clinical trial, as defined in Figure 1 a and Table 1 .
Upon commencement of the clinical trial in the defined population, a sample of individuals from . Black squares indicate HIV prevalence in prostitutes in Nairobi from field studies. Similarly, the squares indicate prevalence in male clients of STD clinics and the circles prevalence in women in general [43] . Introduction of HIV is assumed to occur in 1980. (b) Corresponding HIV incidence curves for the same five repetitions. HIV incidence for female-total and male-total are omitted for clarity. designated risk groups (i.e. sexual activity classes of given sex) are randomized into controls and vaccinees. As defined in Figure 1 b, the number of controls of disease state h, sex k in the activity class i is denoted
. The number of vaccinees at time t of disease state h, sex k and activity class i is defined as Z h k,i (t) (h l 0, …, 5). Vaccinees in state h l 0 represent those in whom protective immunity has not as yet developed post immunization. All vaccinees start in state h l 0 and then pass to state h l 1 once protective immunity has developed after a defined average time delay. The number of vaccinees in whom immunization does not produce any protection (i.e. does not ' take ') is defined as Z h k,i (t) (h l 6, …, 10). Parameter assignments for vaccine characteristics including the mode of vaccine action, vaccine efficacy and the average time-lag (1\l) are specified in each simulation. Table 2 lists the parameter assignments. The time-lag in the development of protection is mirrored by the movement of individuals between two states at the average rate of l. In the first state (h l 0) individuals are fully susceptible to infection, while in the second state (h l 1) susceptibility is reduced to the maximum level induced by the vaccination. Note those who have been vaccinated, but acquire infection due to imperfect vaccine efficacy, are assumed to be as equally infectious as unvaccinated infecteds. Waning of vaccine protection over time post immunization, is represented by individuals totally losing their protection at a rate of ω (i.e. they move directly to Z' k,i (t)). The half life of immunization is taken to be the period from the receipt of vaccination (maximal protection) to when 50 % of individuals lose protection. The adaptation of the basic model to mirror a phase III vaccine trial requires the specification of an additional 31 rates (r l 11, …, 41). These are detailed in Table 1 . Appendix 2 provides details on the Monte-Carlo procedure.
Simulation procedures
The mathematical model is used to generate infection and vaccination events within a simulated phase III trial of a candidate HIV vaccine to investigate the performance of different measures of vaccine efficacy. A variety of simulations are performed with different parameter assignments (see Table 2 ) for true vaccine efficacy (25, 50, 75 %), the mode of vaccine action (Models 1 and 2, plus Mixed and Distributional Models), the waning of vaccine induced immunity (half-lives of 2, 5 and 10 years and lifelong protection) and the time-lag (0, 6 and 12 months). Different behavioural characteristics are examined including heterogeneity in sexual activity (compared with homogeneous activity) and various mixing patterns (proportional, moderate and strong assortativeness). The trial designs considered are cohort based (e.g. CSW, MCSC) with patient follow-up of 2 or 5 years and different periods of recruitment of patients to the trial (all enter at the same time, or over 1, 2n5 and 5 years). Different HIV incidence levels at the start of the trial (0n06, 0n15 and 0n25 person years) and under conditions of rising and falling incidence over the duration of the trial are examined. All simulation trials are assumed to be longitudinal, randomized and double-blind with two arms and that there is no loss to follow-up. Unless otherwise stated, the study population is 4000 in size with an initial incidence of 0n06 per annum in CSW. This type of design is appropriate for the evaluation of the direct effects of vaccination on the individual (efficacy). Total, indirect (i.e. herd immunity) and reduced infectiousness effects can be studied with different types of design [2, 21, 22] .
Values for the epidemiological, behavioural and demographic parameters (Table 2 ) are chosen to represent CSW and MCSW, as well as the general population in a sub-Saharan city such as Nairobi. In the simulated trials, cohorts of CSW have been used primarily because of their high HIV incidence ; however, the model has been adapted to represent cohorts of MCSC as well. The chosen parameter values give rise to the prevalence and incidence curves plotted in Figure 2 (in absence of a clinical trial).
The validation scenario considered is that of homogeneity in sexual activity within a group of CSWs, with three levels of vaccine efficacy under the mode of action defined by Models 1 and 2, plus the Mixed model, with 2 or 5 years of follow-up. However, the second scenario, incorporating heterogeneity in sexual activity (i.e. six sexual activity classes), provides the basic set of parameter assignments for further, more elaborate, trials and assumptions. The different simulations for various parameter assignments and trial designs are grouped into the nine scenarios as listed in Table 3 .
Statistical analyses
For each parameter set 50 repetitions were performed. Except for the chance effects introduced into the Simulation studies of HIV-1 vaccine A new EM based on HARE and HEFT log-spline hazard estimation [29, 30] was applied to a limited number of scenarios. Basically, this approach consists of constructing the hazard curves for vaccinees and controls based on follow-up data. The hazard curves will be functions of time t. Estimation of VE then consists of taking the hazard ratio at a certain t. Brunet and colleagues [23] suggest choosing t l 0 which theoretically should provide valid estimation across different modes of action and in presence of frailty effects. We consider t l 6 months instead to gain precision while striving for validity. The HARE and HEFT methodology is described further in Appendix 3. Upon calculation of HRR, CIR, HARE or HEFT, vaccine efficacy was then estimated by the relationship VE CIR l 1kCIR, VE HRR l 1kHRR. In the case of HARE (or HEFT)
where t l 6 months and h v (t) and h c (t) are the hazard functions of vaccinees and controls estimated by HARE (or HEFT 
Computational details
Numerical results were generated by a program written in FORTRAN and simulations were performed on a SUN Sparc4, 5 and Ultra workstations. HRR and CIR were calculated using SAS Version 6.11, and HARE and HEFT were calculated using S-PLUS Version 3.4. HARE and HEFT software was obtained from StatLib [34] .
RESULTS
Homogeneous sexual behaviour (Scenario 1)
The first scenario examined is that of a vaccine trial with 2 and 5 years of follow-up in a population with homogeneous sexual behaviour. Parameter values for this and subsequent scenarios are documented in Table 3 , and summary statistics are listed in Table 4 .
As expected from previous studies [6, 7, 12, 15] increase from 1n8 to 2n7%, and from 1n8 to 2n6 %, respectively. The pattern is similar for other models of action, efficacies and different periods of follow-up.
Under Model 2, the VE CIR gives the best performance, although adjusting for sexual behaviour seems to contribute nothing to the precision or accuracy.
The measure that performs least well (i.e. VE CIR under Model 1 and VE HRR under Model 2) is typically more biased under heterogeneity is behaviour than homogeneity.
Under the Mixed Model the VE unadj HRR is subject to two competing time-dependent biases. First, is the same negative bias present in Model 1 under heterogeneous sexual activity and second, is the positive bias under the Mixed Model. We observe (see Table 4 ) that at low or moderate efficacy (25 % or 50 %), the VE unadj HRR increasingly underestimates with longer follow-up (the negative bias due to heterogeneity predominates), whereas at high efficacy (75 %) it increasingly overestimates (the bias due to the Mixed Model is more important). However, the VE adj HRR , which is not subject to the negative bias under heterogeneous sexual activity, incurs only a positive bias due to the Mixed Model, and therefore overestimates at all vaccinal efficacies.
In general, under heterogeneity in sexual activity, the VE adj HRR is better at low and medium vaccine efficacy, and the VE CIR is better at high efficacy. With respect to direction of bias, our results are consistent with those of other studies [6, 7, 12, 15] , particularly with Svenssen [17] , who used a somewhat simpler model framework, and Halloran and colleagues [16] , who used frailty mixing models.
Patterns of mixing between sexual activity classes (Scenario 3)
Non-random mixing between different sexual activity classes adds a further source of heterogeneity. We examine the effects on EMs under the assumption of proportional mixing (all individuals have equal preference where couple formation is only restricted by supply and demand [11] ), of moderate assortative mixing (individuals have a five times greater prefer-ence for forming sexual partnerships with people in their own sexual activity class) and strong assortative mixing (preference is ten times). Mixing details are given in Appendix 1. As summarized in In general, non-random mixing exacerbates any biases, whether the direction is positive or negative, that may already be present in other scenarios. In some instances under assortative mixing, precision may increase compared with proportional mixing. This is because the epidemic is more concentrated within the highest sexual activity classes of the population and of the cohort of CSW sampled under assortative mixing, producing a greater proportion of realized endpoints during the clinical trial. These results are in broad agreement with Haber and colleagues [13, 14] who concur that biases for their estimators are more pronounced under non-random than random mixing.
Waning of vaccinal protection over time (Scenario 4)
The effect of waning is investigated in order to determine whether valid estimation of the maximum efficacy is possible with traditional measures. Ideally, we would be able to disentangle the maximum efficacy and the rate of waning in a controlled vaccine trial since both of these vaccine characteristics are meaningful at the public health level. Limiting ourselves to the use of VE HRR and VE CIR without assuming prior knowledge of the waning process, we examine whether the EMs reflect the maximum efficacy.
We find under all three models of vaccine action, a waning in efficacy over time post vaccination induces a negative bias in all of the EMs compared to the true maximum efficacy, even for VE HRR under Model 1 and VE CIR under Model 2. This effect becomes more severe as the half-life of protection decreases (Fig. 3) . These results could produce a false conclusion that a moderate to good vaccine, but with a short duration of protection, has low efficacy. For instance, a vaccine of 50 % maximal efficacy under Model 1 and with a protection half-life of 2 years, would be recorded as having a 38 % and 39 % efficacy by the VE adj HRR at, respectively, 2 and 5 years of follow-up. Under Model 2 the same vaccine would be estimated to have an efficacy of 31 % and 15 % at respectively 2 and 5 years of follow-up. That negative bias is induced upon the EMs (which assume that vaccinal protection is instantaneous and constant) by waning is to be expected since some vaccinees who lose protection during the study will be infected more quickly than if protection were lifelong, thereby causing a considerable underestimation of efficacy. With respect to the use of the wrong measure under a given mode of action, the VE CIR , which is already negatively biased in absence of waning under Model 1, develops a further negative bias as half-life of waning shortens. Also, VE HRR which begins positively biased in absence of waning under Model 2 reverses the direction of its bias with decreasing half-life. Furthermore, note that the positive bias of the VE HRR under Model 2 that is offset by the roughly equivalent negative bias induced by a 5 year half-life of waning can deceptively produce a seemingly accurate estimation. The observed trends are qualitatively the same at different vaccinal efficacies (25 %, 75 %).
The degree of bias observed in some of these results Simulation studies of HIV-1 vaccine can be explained mathematically. Recalling that our model of waning is reflected by total individual loss in protection from the maximum level to zero (rather than gradual decline), the proportion protected is a function of time (α l α(t)), while the reduction in susceptibility drops from its maximum value to zero (δ l maximum value before waning, δ l 0 after waning). To explain the bias, consider a vaccine with a duration of protection assumed to be exponentially distributed with a mean of 2 years. Then we calculate over the course of an n-year long trial that the average proportion who are protected can be given by
For a 2 year follow-up, this integral gives 63n2%, which when multiplied by the maximum efficacy of 50 % gives 31n6 %. 
Time-lags in protection post immunization (Scenario 5)
As under waning, we examine the ability of the traditional EMs to estimate to maximum vaccinal efficacy under time-lags in the generation of immunity. The effect of this temporal change in efficacy over time is illustrated in Figure 4 for a vaccine of 50 % efficacy. Under Models 1 and 2, plus the Mixed Model, the underestimation of vaccine efficacy by the VE HRR and VE CIR measures increases as the duration of the delay rises. This is to be expected, since the window of susceptibility post immunization will give rise to some cases of infection in vaccinated individuals. Some suggest that this time-lag could last until the third booster, after which maximum protection might be achieved. For Model 1 and the Mixed Model the negative bias in the VE HRR may be reduced by long periods of follow-up. However, the bias is exacerbated (expectedly so) by long follow-up with the VE CIR . Under the Mixed Model the VE HRR performs better than the VE CIR at moderate efficacy. More generally, neither the VE HRR nor the VE CIR can offer reliable and unbiased estimation for any mode of vaccine action without prior information on time-lag. For instance, under a 6 month time-lag and 50 % efficacy under the Mixed Model, the VE adj HRR would recognize 44 % efficacy at 2 years of follow-up, while the VE unadj CIR would detect 38 %.
Heterogeneity in the response to vaccination (Scenario 6)
Heterogeneity in response to vaccination was investigated assuming all vaccinees (100 % take) benefited from some individual level of protection selected from a Normal distribution with mean of µ δ l 50 % and a standard deviation (..) of σ δ l 8%, 16n7 % or 25 %.
An .. of 8 % corresponds to a normal distribution with µ δ p3σ δ contained within the interval [0n25, 0n75]. Similarly, an .. of 16n7 % corresponds to µ σ p3σ δ contained within [0, 1] and an .. of 25% to µ δ p2σ δ contained within [0, 1]. Also, considered was a normal distribution with mean µ δ l 66 % and 75 % take. As illustrated in Figure 5 , results at 5 years of follow-up show the relative bias of the VE adj HRR and VE unadj HRR to increase gradually under the Distributional Model at 75 % and 100 % take. On the other hand, the negative bias of VE CIR under Model 1 is reduced substantially in passing from Model 1 (.. l 0) to the Distributional Model, and continues to do so with increasing variance σ# δ . The VE CIR still underestimates the true vaccinal efficacy, however. The VE adj HRR is the best estimator under this mode of vaccine action with relative bias increasing gradually with increasing variance in vaccinal efficacy. Our results concur with those of Svenssen [17] who also report positive bias under heterogeneity in vaccinal response.
For a sufficiently long follow-up, it is natural that bias in estimates rise with increasing σ# δ since Simulation studies of HIV-1 vaccine Take and mean efficacy of first vaccine are set at α l 1n0, µ δ l 50 % and that of the second vaccine are set at α l 0n75, µ δ l 67 %. Follow-up period is 5 years. Other parameter values are as explained in Table 3 . Barplots indicate the 5th, 25th, 50th, 75th and 95th percentile of the efficacy measures calculated over the 50 repetitions.
individuals at the low end of the distribution will approach a zero reduction in susceptibility almost as total vaccine failures as in Model 2 non-takers. Thus the Distributional Model can take on properties of Model 2. Furthermore, with larger variance in vaccinal efficacy, greater proportions of vaccinees will be infected earlier on average leaving the remaining vaccinees with higher average levels of protection than under small variances. This is reflected in the VE adj
HRR
and VE unadj CIR which are seen to increase with increasing variance in vaccinal efficacy when the follow-up period is sufficiently long.
Understandably, the precision of the measures may decrease with increasing variance of the distribution in reduction in susceptibility. For example, at 2 years of follow-up the .. increases from 2n7 % to 3n5 % and 2n6 % to 3n4% of VE adj HRR and VE unadj CIR respectively in going from a distribution with σ δ l 0 % to one with σ δ l 8 %. Thus, potentially the Distributional Model may have a non-negligible effect on variance of EMs which may play an important role during sample size considerations, at least for short follow-up periods.
Study population (Scenario 7)
A comparison was made between two types of study population, namely, MCSC and female CSW under identical conditions of sample size, vaccine efficacy, trial design and baseline incidence. In these settings the VE HRR and VE CIR are less prone to biases caused by the mode of vaccine action, mixing and efficacy levels in cohorts of MCSC. However, all measures show a high degree of variability in MCSC than in CSW, particularly with low efficacy vaccines. This is due to the faster rate of spread of HIV in the latter group (i.e. more events occur). Since the precision of the VE CIR is time dependent under Model 1, the measure develops bias more quickly in a CSW cohort than in the MCSC cohort due to the more rapid accumulation of events in the former by comparison with the latter. Similarly, the VE HRR under Model 2 develops a positive bias more quickly in a CSW cohort than the equivalent MCSC cohort. The rise in variability in the MCSC setting is due to the smaller number of infection endpoints. There thus arises a conflict between improving the statistical precision or validity. Validity is enhanced within the MCSC setting, while precision is greater within the CSW setting.
Accrual of patients during the conduct of the trial (Scenario 8)
The question of interest in this scenario is whether the strategy of recruiting subjects during the conduct of the trial can act to counter frailty selection. Recruitment permits replacement of the most vulnerable trial participants. However, accrual periods of 1, 2n5 and 5 years, in combination with 2 and 5 years of follow-up of every patient recruited, did not significantly improve the performance of the EMs in either cohorts of CSWs or MCSCs. Although the biases were reduced for long follow-up periods in the VE CIR under Model 1 and the Mixed Model, and in the VE HRR under Model 2, this was largely due to the fact that the epidemic moved to a more stable endemic level when both follow-up and recruitment period are lengthy, rather than due to any special merit of patient accrual.
Changing HIV incidence over the conduct of the trial (Scenario 9)
In this scenario we examine varying levels of HIV incidence at the start of the trial and changes therein over its conduct. Because at different phases in the epidemic curve it was not possible to recruit 4000 uninfected prostitutes in our population, sample size was fixed at 300. Simulation results for incidence of 15 % (rising), 25 % (rising) and 25 % (falling) are given in Table 4 . The .. of the measures are also excluded because of the small sample size. The VE HRR in Model 1 and VE CIR in Model 2 do not incur appreciably any new biases due to the different incidence levels. However, the bias present for the VE CIR in Model 1 and VE HRR in Model 2 is larger with higher initial incidence in the rising phase. This bias, however, declines with decreasing initial incidence in the dropping phase. In fact, at incidence of 15 % and falling, the wrong measures (VE CIR under Model 1 and VE HRR under Model 2) perform almost as well as the right measure in terms of bias (not shown in Table  4 ). Similarly, under the Mixed Model the EMs are least biased at incidence of 15 % and falling compared to the other three incidence levels.
At incidence of 15 % and falling, the change in HIV incidence is very slow and almost constant, in contrast with the other three phases of incidence. That the EMs are less biased at 15 % and falling follows the same reasons given for the reduced bias in EMs under cohorts of MCSC (scenario 7). In general, these analyses reveal that biases are generated by rapidly rising incidence and that there may be practical problems in recruiting sufficient uninfecteds at certain times in the epidemic's development.
Hazard Regression (HARE) and Hazard Estimation (HEFT)
Given the numerous potential biases in traditional EMs we explore the use of log-spline models to obtain valid estimation of vaccinal efficacy across different modes of vaccine action and possible frailty effects. This approach is in part motivated by Brunet and colleagues [23] . . However, this increased robustness is achieved at the cost of greater variability. VE HARE and VE HEFT were obtained using t l 6 months after calculating hazard curves based on 2 years of followup data (see Statistical Analyses in Methods section regarding need to choose t). This choice of t was suitable for striking a balance between validity and precision, contrary to Brunet's suggestion of t l 0, where precision is low. How VE HARE and VE HEFT perform under a broader range of conditions is the subject of another study.
DISCUSSION
At present it seems unlikely that the vaccinal properties such as mode of action, time-lag post Simulation studies of HIV-1 vaccine with VE HEFT , VE HARE under Models 1, 2 and Mixed of vaccine action and the basic scenario (scenario 2), assortative mixing (scenario 3) and 10 year vaccinal waning (scenario 4). Parameter values are as described in Table 3 . Barplots indicate the 5th, 25th, 50th, 75th and 95th percentile of the efficacy measures calculated over the 50 repetitions.
immunization and waning rate of a candidate HIV vaccine will be known with precision before the conduct of a phase III trial, given current uncertainty over which immunological measures correlate best with protection against infection. It is hoped that the trials themselves will yield important information on these correlates. However, trial design raises many difficult issues which must be addressed if we are to understand how different candidate vaccines perform under conditions of natural exposure to infection. The real dilemma is that the choice of an EM, the design of the trial and concomitantly sample size determination, each depend on the precise properties of the vaccine and its mode of action. Given this somewhat unhappy state of affairs, the issue in question at present is what EM performs best both for the possible range of vaccinal properties, and in the presence of the many sources of heterogeneity that influence HIV transmission in sexually active populations.
Our simulation studies provide a series of important guidelines, although further research is required to explore new directions for EMs in a wider variety of settings. The factors influencing the performance of a defined EM for the three major possible modes of vaccine action were explored using a model framework incorporating the biological characteristics of HIV transmission and infection specifically designed to mimic the dynamics of HIV-in a population with heterogeneous sexual activity. The shortcomings of VE measures are observed despite proper randomization at the start of the trial. With time, randomization fails to keep the individual characteristics balanced between the two groups.
Given the sexual behaviour is highly heterogeneous in human communities [35] , this important facet of HIV transmission was incorporated in our simulations. Our analyses first suggest that the validity of VE CIR and VE HRR measures is most likely unsatisfactory for all modes of vaccine action. In both heterogeneous and homogenous populations accurate estimation of vaccinal efficacy will be difficult using VE CIR and VE HRR given the mode of vaccine action may not be known. The problem of maintaining accuracy is further exacerbated by non-random mixing, which tends to amplify any biases that already exist under random mixing. Here again, observational studies suggest that in many settings the observed pattern of mixing could be assortative [36] . Of the traditional measures the VE adj HRR appears to be the most reliable in these circumstances, except under the Model 2 mode of vaccine action. Adjustment of measures for sexual activity implies, of course, the importance of behavioural questionnaires for the study population. Rida [37] also has suggested that behavioural data will be essential to assess whether vaccination itself induces changes in sexual activity and therefore unequal exposure in control and treated groups.
The different possible modes of vaccine action could present yet another hurdle if more than one vaccine is tried in multi-armed trials. If the same statistical measure is used to compare two vaccines with different modes of action, then adequate evaluation of vaccine efficacy may not be achieved. For example, if the VE HRR is used to compare a vaccine of Model 1 with one of Model 2 of equal efficacy, it is possible that the latter vaccine may be viewed as more effective due to the time dependent overestimation of VE HRR under Model 2. In this case, differences in the survival curves (proportion of uninfected individuals at time t) between the two candidates will be due to the different modes of vaccine action since both vaccines have the same efficacy. Obviously, comparability of such candidates between trials with separate control groups is even more problematic.
However, the factors that have the greatest influence on accuracy of the EMs are waning immunity post immunization and time delays in the development of protection post vaccination. Unless additional information is available on these processes, trials will tend to underestimate true maximum efficacy. Even if average duration of time-lag and rate of waning were known, it remains to be seen whether this information would then permit correction of the traditional EMs to accurately estimate the maximum vaccine efficacy. Thus, changing efficacy over time makes trial data analysis and interpretation of vaccine efficacy estimates even more tenuous. Underestimation of true efficacy is particularly wearisome since maximum efficacy is not expected to be high for the early products that enter phase III trials [28] . Hence, ample underestimation of true efficacy could lead to the rejection of a reasonably efficacious product which may have some public health interest in certain populations [28] . This could result in a missed chance to distribute a moderately effective vaccine.
The high bias of the EMs under waning immunity and time delays in the development of protection suggest that confidence bounds derived by Halloran and colleagues [8] are unlikely to be respected. Their lower bound is based on their Model 2 estimator and upper bound based on their Model 1 estimator. Our Model 2 and Model 1 estimators are seen on average not to encompass the true maximal value under timelag and waning influences. One way to elude the problem of waning immunity could be to administer boosters during the course of the trial in order to maintain the level of protection constant.
A distributional mode of vaccine action will also influence variability and bias. Additional bias can arise due to this mode of vaccine action, but is likely to be minor and will probably manifest only if followup is lengthy. The Distributional Model may play a more important role in variability of measures.
Results from the Cohort of MCSC, accrual and incidence scenarios share a common thread by demonstrating the importance of the epidemic shape on the quality of estimation. Accuracy may be improved by careful choice of a study setting (i.e. cohort type). Male attendees at sexually transmitted disease clinics have many advantages in terms of striking a sensible balance between the rate at which infection events more likely to occur and the size of the potential study population. Female CSW are very appropriate in terms of their high rates of infection, but sample size issues may restrict their potential value (i.e. they are a small proportion of the sexually active population and many are already likely to be infected in high transmission areas). A further consideration with respect to high incidence groups such as MCSC and CSW, is the high variability in sexual activity within these population strata. This can menace validity of the EMs. There is thus a dilemma between using lower activity groups to gain validity versus high transmission groups to gain precision in EMs.
Staggered entry in trial design (accrual) was in ineffective in limiting frailty or other time dependent effects. This, however, was because accrual requires lengthening the study duration in rapidly changing incidence phases in this particular cohort of CSW. Simulation studies of HIV-1 vaccine Similarly in the incidence scenario, biases were dependent on the incidence phase of the epidemic. Higher incidence rates and rising incidence at start of the study generally produced greater bias than lower incidence rates and falling incidence rates. Overall, therefore, it is difficult to eliminate bias in the complex and heterogeneous settings in which HIV spreads in a community. Furthermore, our simulations do not take account of the added complications of loss to follow-up which will probably act to further decrease precision. This is of obvious importance in the choice of a suitable cohort setting. For example, MCSC may be ideal in terms of incidence and population size, but they may be less reliable in terms of drop out in follow-up.
It is worth noting that under all the conditions investigated (except time-lag), biases of the EM actually increased with follow-up duration. While epidemiological principles suggest that the prospective cohort study involving incident cases and a short follow-up duration is the best observational design to test an aetiologic hypothesis [31] , our study helps to delineate what is meant exactly by a short follow-up. Specifically, clinical trials with follow-up exceeding 2 years in an epidemic condition, such as that considered in this paper, will vary likely encompass increasingly important biases.
Playing a role in the steering of HIV clinical trials, the interim monitoring board will need to consider many factors such as time-lag post-immunization so as not to prematurely conclude from interim analyses that a vaccine is of low-efficacy. Nor should the monitoring board allow trials to continue too long in order to minimize effects of different sources of heterogeneity or waning which would cause underestimations of the true potential of a vaccine.
Clearly, it seems reliable estimations will come only when the mode of action is known a priori to be either Model 1, 2 or Distributional (with 100 % take) and in absence of any time-lag or waning, prerequisites which may demand a stretch of imagination. In any eventuality, we (clinicians, public health experts, immunologists and others) still want to know whether a vaccine works and how well. With this goal in mind, the factors affecting bias and variability of the VE CIR and VE HRR become important.
The importance of having an unbiased (valid) summary statistic of vaccine efficacy is not merely academic. As stated by Kleinbaum [31] : ' […] it is important to recognize that internal validity is the sine qua non of etiologic research […] '. It has numerous clinical and public health implications. On the clinical side, it is important that the statistics used correctly reflect the size of the effect of vaccine [38, 39] . Moreover, with unbiased estimation of vaccine efficacy in combination with survival curves and immunological data, it may be easier to speculate on the mode of vaccine action. As clearly emphasized in past years [39] , it is not enough to detect a significant difference between groups. It is also important to quantify the difference in a meaningful manner [38] [39] [40] . This is well illustrated by the controversy that followed the results of a malaria vaccine trial in Tanzania where an efficacy of 31 % (VE IDR ) was found with a 95 % CI ranging from 0 % to 52 % [41] . Given this level of efficacy and wide confidence interval, the decision to use the vaccine as a public health measure is not straightforward [38] . We have to know what we have on hand to make well-informed decisions. From a public health perspective it is therefore important to disentangle the issues on vaccine efficacy not only to help identify who gets infected (between vaccinees and controls) and who doesn't, but also how many. For example, without prior information on the mode of vaccine action, comparisons of survival curves in multi-armed trials may be difficult to interpret especially if the curves cross. Finally, the preventive potential of a vaccine at a population level (the effectiveness), depends not only on the efficacy of the vaccine but also on the vaccine mode of action [24] . For a fixed vaccine efficacy of 31 %, McLean and Blower [24] , showed that the equilibrium seroprevalence of infection is larger under Model 1 and the Mixed Model than under Model 2. This emphasizes the need for careful interpretation of vaccine efficacy estimates if we want to predict the effectiveness of future immunization programmes. After all, if we cannot deduce the true potential of a vaccine in a clinical trial, how can we expect to be able to approve and distribute a vaccine of public health interest to control the HIV\AIDS epidemic ?
Despite the numerous influences that will be present in HIV vaccine trials, there is some hope that accurate efficacy estimation can be afforded by applying VE HEFT and VE HARE to the method originally proposed by Brunet and colleagues [23] . Their suggestion of basing the analysis on the entry point of time (t l 0) seems sub-optimal, since we find greater precision using the time of 6 months post entry. This time of estimation gives more robust estimates and reduces effects of frailty. In particular, HARE and HEFT offer hope for valid estimation of VE across modes of vaccine action. However, more research is needed in this area both to examine the robustness of this conclusion under a wider range of settings and to derive better estimates of efficacy in heterogeneous study populations. A more general search for robust EMs is also needed. While we may not be able to eliminate bias, it is very important to understand its direction in a defined study population and with a vaccine of a given mode of action. Such an understanding will be important in the appropriate choice of sample size and study duration. Much can be learnt by the sensible use of stochastic simulation models of HIV transmission that incorporate the details of a specific trial design. Prior to implementation of phase III vaccine trials in defined study populations, such studies will help to save time and money in the planning stages, aid in the interpretation of results and in making informed conclusions in HIV vaccine clinical trials. Simulation studies of HIV-1 vaccine Thus, the mixing matrix elements φ k,i,j (t) are the probability that a person of sex k class i chooses a partner of opposite sex kh and class j. The first two constraints are self-explanatory. The third, balancing supply with demand, indicates that the number of partners formed by individuals of sex k and activity class i who choose a member of the opposite sex kh and class j must equal the number of partners formed by sex kh and activity class j who choose a member of the opposite sex k and class i. In order for the supply and demand constraint to hold for all i, j and k at all t, the elements of the preference matrix W k,i,j (and hence the mixing matrix, φ k h ,j,i (t)) should satisfy for all i and j the following constraint :
Purely assortative mixing (mixing exclusively within same activity class) occurs when W k,i,j l 1 for i l j and W k,i,j l 0 for i j. Random or proportionate mixing occurs when W k,i,j l 1 for all values of k, i and j.
APPENDIX 2
In the stochastic simulations, a random sequence of individual events is generated where each of the 492 possible events (2 sexesi6 classesi41 events) occurs with probability P r,k,i (t) defined by P r,k,i (t) l R r,k,i (t)\S(t), where S(t) l Σ r,k,i R r,k,i (t). Using RAN2 [42] , the event chosen at each step of the sequence is determined by a random number generated from a uniform distribution according to the 492 probabilities. The time a person of sex k and class i spends in a specific state r before making a transition is assumed to be exponentially distributed with mean R −" r,k,i (t). Furthermore, the time between any two events is exponentially distributed with mean S −" (t). Therefore, the time of occurrence s of chosen event r can be determined by choosing a random number from a uniform distribution and setting it equal to F(s) in the equation F(s) l 1kexp[kS(t) s]. Thus by an iterative process, a sequence of events and their time of occurrence is generated.
